BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ye S, Zhao XY, Hu XG, Li T, Xu QR, Yang HM, Huang DS, Yang L. TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma. Oncol Rep 2017;37:2215-26. [PMID: 28350084 DOI: 10.3892/or.2017.5494] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Yan L, Zhang Z, Liu Y, Ren S, Zhu Z, Wei L, Feng J, Duan T, Sun X, Xie T, Sui X. Anticancer Activity of Erianin: Cancer-Specific Target Prediction Based on Network Pharmacology. Front Mol Biosci 2022;9:862932. [DOI: 10.3389/fmolb.2022.862932] [Reference Citation Analysis]
2 Jie M, Hai-xia L, Fei-fei T, Shu-ling L, Tian-yi F, Xue-qian W, Qing-guo W, Fa-feng C. Systematic Investigation of Berberine for Treating Hepatocellular Carcinoma Based on Network Pharmacology. Digital Chinese Medicine 2019;2:127-35. [DOI: 10.1016/j.dcmed.2019.12.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
3 Yao TH, Pataer P, Regmi KP, Gu XW, Li QY, Du JT, Ge SM, Tu JB. Propranolol induces hemangioma endothelial cell apoptosis via a p53BAX mediated pathway. Mol Med Rep. 2018;18:684-694. [PMID: 29767244 DOI: 10.3892/mmr.2018.9013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
4 Wang XK, Liao XW, Yang CK, Liu ZQ, Han QF, Zhou X, Zhang LB, Deng T, Gong YZ, Huang JL, Huang R, Han CY, Yu TD, Su H, Ye XP, Peng T, Zhu GZ. Oncogene PLCE1 may be a diagnostic biomarker and prognostic biomarker by influencing cell cycle, proliferation, migration, and invasion ability in hepatocellular carcinoma cell lines. J Cell Physiol 2020;235:7003-17. [PMID: 32037547 DOI: 10.1002/jcp.29596] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Li C, Zhang W, Yang H, Xiang J, Wang X, Wang J. Integrative analysis of dysregulated lncRNA-associated ceRNA network reveals potential lncRNA biomarkers for human hepatocellular carcinoma. PeerJ 2020;8:e8758. [PMID: 32201648 DOI: 10.7717/peerj.8758] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kong F, Kong D, Yang X, Yuan D, Zhang N, Hua X, You H, Zheng K, Tang R. Integrative analysis of highly mutated genes in hepatitis B virus-related hepatic carcinoma. Cancer Med 2020;9:2462-79. [PMID: 32017470 DOI: 10.1002/cam4.2903] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Fussey JM, Vaidya B, Kim D, Clark J, Ellard S, Smith JA. The role of molecular genetics in the clinical management of sporadic medullary thyroid carcinoma: A systematic review. Clin Endocrinol 2019;91:697-707. [DOI: 10.1111/cen.14060] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
8 Sun Y, Chen ZY, Gan X, Dai H, Cai D, Liu RH, Zhou JM, Zhang HL, Li ZH, Luo QQ, Jiang S, Wang T, Zhang KH. A novel four-gene signature for predicting the prognosis of hepatocellular carcinoma. Scand J Gastroenterol 2022;:1-11. [PMID: 35512233 DOI: 10.1080/00365521.2022.2069476] [Reference Citation Analysis]
9 Shi Q, Xue C, Yuan X, He Y, Yu Z. Gene signatures and prognostic values of m1A-related regulatory genes in hepatocellular carcinoma. Sci Rep 2020;10:15083. [PMID: 32934298 DOI: 10.1038/s41598-020-72178-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
10 Sadeghi S, Bejjani A, Finn RS. Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma. Surg Oncol Clin N Am 2019;28:695-715. [PMID: 31472914 DOI: 10.1016/j.soc.2019.06.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Zhang H, Bao J, Zhao S, Huo Z, Li B. MicroRNA-490-3p suppresses hepatocellular carcinoma cell proliferation and migration by targeting the aurora kinase A gene (AURKA). Arch Med Sci 2020;16:395-406. [PMID: 32190151 DOI: 10.5114/aoms.2019.91351] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
12 Chao X, Jia Y, Feng X, Wang G, Wang X, Shi H, Zhao F, Jiang C. A Case-Control Study of ADCY9 Gene Polymorphisms and the Risk of Hepatocellular Carcinoma in the Chinese Han Population. Front Oncol 2020;10:1450. [PMID: 32983975 DOI: 10.3389/fonc.2020.01450] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Duan X, Cai Y, He T, Shi X, Zhao J, Zhang H, Shen Y, Zhang H, Zhang H, Duan W, Jiang B, Mao X. The effect of the TP53 and RB1 mutations on the survival of hepatocellular carcinoma patients with different racial backgrounds. J Gastrointest Oncol 2021;12:1786-96. [PMID: 34532128 DOI: 10.21037/jgo-21-312] [Reference Citation Analysis]
14 Liu C, Li F, Li X, Cao M, Feng G, Yuan X, Shi X. WIPI2 depletion inhibits the growth of hepatocellular carcinoma cells through the AMPK signaling pathway. Oncol Rep 2020;43:1467-78. [PMID: 32323845 DOI: 10.3892/or.2020.7531] [Reference Citation Analysis]